Methotrexate and mucositis: A merry-go-round for oncologists

High-dose methotrexate is the backbone of various regimens for treating lymphoid malignancies. Mucositis is a well-known, dose-related side effect of methotrexate. Prophylactic measures such as folinic acid rescue are useful but do not prevent mucositis in all the cases. Once severe mucositis (WHO G...

Full description

Saved in:
Bibliographic Details
Main Authors: Kundan Mishra, Aditya Jandial, Anil Kumar, Deepesh Lad, Gaurav Prakash, Alka Khadwal, Pankaj Malhotra
Format: Article
Language:English
Published: Thieme Medical and Scientific Publishers Pvt. Ltd. 2019-01-01
Series:Indian Journal of Medical and Paediatric Oncology
Subjects:
Online Access:http://www.ijmpo.org/article.asp?issn=0971-5851;year=2019;volume=40;issue=1;spage=150;epage=152;aulast=Mishra
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:High-dose methotrexate is the backbone of various regimens for treating lymphoid malignancies. Mucositis is a well-known, dose-related side effect of methotrexate. Prophylactic measures such as folinic acid rescue are useful but do not prevent mucositis in all the cases. Once severe mucositis (WHO Grade IV) sets in, mortality is very high. The index case highlights the natural course of methotrexate-induced mucositis and the need for swift and preemptive intervention.
ISSN:0971-5851
0975-2129